Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTX-101
- Development stage
- Unknown
- Lead developer
- Repeat Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
RTX-101 is an antisense oligonucleotide (ASO) therapeutic candidate developed by Repeat Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with hexanucleotide repeat expansions in the C9orf72 gene. The drug is designed to selectively target and degrade the sense and/or antisense transcripts containing the G4C2 repeat expansion, thereby preventing the formation of toxic RNA foci and the translation of neurotoxic dipeptide repeat (DPR) proteins. These DPR proteins and RNA foci are central to the pathogenesis of C9orf72-mediated neurodegeneration. RTX-101 is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and pharmacokinetic profile following intrathecal administration in patients with ALS.
02
Targets
Chromosome 9 open reading frame 72 hexanucleotide repeat expansion
Beyond the preview
Go deeper on RTX-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTX-101.